| Lipid-based nanoparticles for nucleic acid delivery. | |
| | |
MedLine Citation:
|
PMID: 17252188 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Lipid-based colloidal particles have been extensively studied as systemic gene delivery carriers. The topic that we would like to emphasize is the formulation/assembly of lipid-based nanoparticles (NP) with diameter under 100 nm for delivering nucleic acid in vivo. NP are different from cationic lipid-nucleic acid complexes (lipoplexes) and are vesicles composed of lipids and encapsulated nucleic acids with a diameter less than 100 nm. The diameter of the NP is an important attribute to enable NP to overcome the various in vivo barriers for systemic gene delivery such as: the blood components, reticuloendothelial system (RES) uptake, tumor access, extracellular matrix components, and intracellular barriers. The major formulation factors that impact the diameter and encapsulation efficiency of DNA-containing NP include the lipid composition, nucleic acid to lipid ratio and formulation method. The particle assembly step is a critical one to make NP suitable for in vivo gene delivery. NP are often prepared using a dialysis method either from an aqueous-detergent or aqueous-organic solvent mixture. The resulting particles have diameters about 100 nm and nucleic acid encapsulation ratios are >80%. Additional components can then be added to the particle after it is formed. This ordered assembly strategy enables one to optimize the particle physico-chemical attributes to devise a biocompatible particle with increased gene transfer efficacy in vivo. The components included in the sequentially assembled NP include: poly(ethylene glycol) (PEG)-shielding to improve the particle pharmacokinetic behavior, a targeting ligand to facilitate the particle-cell recognition and in some case a bioresponsive lipid or pH-triggered polymer to enhance nucleic acid release and intracellular trafficking. A number of groups have observed that a PEG-shielded NP is a robust and modestly effective system for systemic gene or small interfering RNA (siRNA) delivery. |
| | |
Authors:
|
Weijun Li; Francis C Szoka |
Related Documents
:
|
17614288 - Retention behavior of phenoxyacetic herbicides on a molecularly imprinted polymer with ... 11742648 - Determination of a universal nucleic acid extraction procedure for pcr detection of gas... 18585458 - Nucleic acid sensing toll-like receptors in dendritic cells. 12831908 - Fluorescence in situ hybridisation for the identification and characterisation of proka... 15784478 - Effect of enterally administered n-3 polyunsaturated fatty acids in acute pancreatitis-... 2271738 - Role of intracellular organelles in the hepatic transport of bile acids. |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Review |
Journal Detail:
|
Title: Pharmaceutical research Volume: 24 ISSN: 0724-8741 ISO Abbreviation: Pharm. Res. Publication Date: 2007 Mar |
Date Detail:
|
Created Date: 2007-05-31 Completed Date: 2007-09-20 Revised Date: 2007-12-03 |
Medline Journal Info:
|
Nlm Unique ID: 8406521 Medline TA: Pharm Res Country: United States |
Other Details:
|
Languages: eng Pagination: 438-49 Citation Subset: IM |
Affiliation:
|
Departament of Biopharmaceutidal Sciences, School of Pharmacy, University of California at San Francisco, San Francisco, California 94143-0046, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Humans Lipids / chemistry* Models, Biological Nanocapsules / chemistry* Nucleic Acids / chemistry, genetics*, pharmacokinetics Transfection / methods* |
| Grant Support | |
ID/Acronym/Agency:
|
EB003008/EB/NIBIB NIH HHS; GM61851/GM/NIGMS NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Lipids; 0/Nanocapsules; 0/Nucleic Acids |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Synthetic activity enhancement of membrane-bound lipase from Rhizopus chinensis by pretreatment with...
Next Document: Intestinal absorption of miltefosine: contribution of passive paracellular transport.